Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome.
Serious carbamazepine hepatotoxicity is being recognized more frequently and is usually manifest as an acute granulomatous hepatitis that is self-limiting if the drug is withdrawn. The case of a 59-year-old man who developed the vanishing bile duct syndrome after 2 months of treatment with carbamazepine for glossopharyngeal neuralgia is reported. The characteristic histological features of this syndrome may also be seen in primary biliary cirrhosis, primary sclerosing cholangitis, graft-vs.-host disease after allogeneic bone marrow transplantation, chronic liver allograft rejection, and other drug reactions. The progress of this patient to date suggests that irreversible liver injury resulting in chronic liver disease is likely, in keeping with the clinical course of the vanishing bile duct syndrome in most cases.
Forbes
G M
GM
Gastroenterology/Liver Unit, Sir Charles Gairdner Hospital, Perth, Australia.
Jeffrey
G P
GP
Shilkin
K B
KB
Reed
W D
WD
D001652:Bile Ducts / Q000187:drug effects / Q000473:pathology*; D002220:Carbamazepine / Q000009:adverse effects*; D015209:Cholangitis, Sclerosing / Q000150:complications; D006086:Graft vs Host Disease / Q000150:complications; D006801:Humans; D008099:Liver / Q000187:drug effects*; D008105:Liver Cirrhosis, Biliary / Q000150:complications; D008297:Male; D008875:Middle Aged; D013577:Syndrome
D002220:Carbamazepine